The addition of the immune therapy motolimod to pegylated liposomal doxorubicin failed to improve overall survival among women with recurrent epithelial ovarian carcinoma in a randomized phase II trial.
A long-term phase III trial found that maintenance chemotherapy did not improve overall survival over surveillance among women with advanced ovarian/fallopian tube/peritoneal cancer who had a complete response to first-line therapy.
In this interview we discuss the idea behind an enhanced recovery program for patients undergoing cytoreductive surgery for ovarian cancer, as well as some of the potential cost savings.
Molecular expression analysis found that high-grade serous ovarian carcinomas exhibit significant alterations to cell cycle genes, DNA damage genes, and other pathways following treatment with neoadjuvant chemotherapy.
Event-free survival was not maintained in children and adolescents with intermediate-risk malignant germ cell tumors when cisplatin-based chemotherapy was reduced from four to three cycles and compressed from 5 to 3 days per cycles.
A small study found that it is feasible to detect BRCA1/2 reversion mutations in circulating cell-free DNA in patients with recurrent high-grade serous ovarian cancer. Those reversion mutations can help predict poor response to therapy in these patients.
Woman who undergo bilateral removal of ovaries at the time of hysterectomy have higher risks of all-cause mortality afterward, including hospital admission for ischemic heart disease.
An analysis of Lynch syndrome–associated ovarian cancer found that the malignancy tends to present at an early stage and has a generally good prognosis.
Women with endometrioid ovarian cancer present at a younger age and with earlier stage disease than those with serous ovarian cancer, according to a new analysis. The earlier presentation resulted in better 5- and 10-year overall survival rates as well.
The FDA granted accelerated approval to rucaparib (Rubraca), a PARP inhibitor, for the treatment of women with deleterious BRCA mutation-associated ovarian cancer.